The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
The portfolio includes foundational patents on the production, composition, and commercial use of NR
The company also reported significant progress toward its internally defined Sustainable Development Goals
The additional production will raise the installed capacity by 400 million and available capacity by 240 million at the facility
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease
The company operates a chain of mid-sized multi-speciality hospitals
Subscribe To Our Newsletter & Stay Updated
